Press releases

1. 
   

2. December 15, 2009 - Alethia Biotherapeutics announces the nomination of Dr. Michael Berendt to the Board of Directors
   

3. December 7, 2009 - Alethia Biotherapeutics in-licenses a peptide for imaging of solid tumors in vivo and announces positive pre-clinical results of AB-16B5 in prostate and breast cancer
   

4. November 30, 2009 - Alethia Biotherapeutics collaborators at the NRC-BRI publish results in Oncogene on the role of secreted clusterin as an important mediator of EMT
   

5. May 26 2009 - Alethia Biotherapeutics extends its collaborative agreement with Biosite for monoclonal antibody development
   

6. May 6, 2009 - Alethia Biotherapeutics exercises its license option with NRC-BRI
   

7. April 23, 2009  - Alethia Biotherapeutics closes a $2.2 M financing
   

8. February 17, 2009 - Yves Cornellier, president and CEO Alethia Biotherapeutics, nominated to the Board of Directors of Montreal in Vivo
   

9. April 3, 2008 - BDC Venture Capital and GO Capital invest in Alethia Biotherapeutics
   

10. October 3, 2007 - Alethia Biotherapeutics Inc. announces in-licensing of family of monoclonal  antibodies to treat metastatic cancer
    

11. May 1, 2007 - Alethia Biotherapeutics Inc. and Emerillon Therapeutics Inc. announce collaborative agreement for target discovery in bone-related diseases
    

12. March 12, 2007 - Alethia Biotherapeutics Inc.  announces collaborative agreement with Biosite for antibody development in ovarian cancer
    

13. June 23, 2006 - Alethia Biotherapeutics Inc. announces the filing of a patent application of ovarian cancer-specific targets
    

14. February 13, 2006 - Alethia Biotherapeutics Inc. announces the filing of a patent application of  osteoclast-specific targets
    

15. December 19, 2005 - Alethia Biotherapeutics Inc. announces the filing of a PCT patent application for its bone-related validated targets
    

16. August 3, 2005 - Alethia Biotherapeutics Inc. appoints Mr. Yves Cornellier as President and Chief Executive Officer

CONTACT US

FRANÇAIS

HOME

ABOUT US

RESEARCH AND DEVELOPMENT

BUSINESS DEVELOPMENT

MEDIA CENTER